Search research articles
Contact Us
Filters
Showing results (1-10 of 73) with videos related to
Page
of 8
Sort By:
Biometrical Journal. Biometrische Zeitschrift
|
April 25, 2017
Using predictions from a joint model for longitudinal and survival data to inform the optimal time of intervention in an abdominal aortic aneurysm screening programme
Michael J Sweeting
Pharmaceutical Statistics
|
March 14, 2012
Escalation strategies for combination therapy Phase I trials
Michael J Sweeting, Adrian P Mander
Statistics in Medicine
|
January 30, 2015
A product of independent beta probabilities dose escalation design for dual-agent phase I trials
Adrian P Mander, Michael J Sweeting
Biometrical Journal. Biometrische Zeitschrift
|
August 12, 2011
Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture
Michael J Sweeting, Simon G Thompson
Plos One
|
July 13, 2016
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Statistics in Medicine
|
December 2, 2005
Bayesian back-calculation using a multi-state model with application to HIV
Michael J Sweeting, Daniela De Angelis, Odd O Aalen
Statistics in Medicine
|
April 30, 2004
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
Michael J Sweeting, Alexander J Sutton, Paul C Lambert
Statistics in Medicine
|
March 16, 2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Biometrical Journal. Biometrische Zeitschrift
|
September 4, 2018
Biases incurred from nonrandom repeat testing of haemoglobin levels in blood donors: Selective testing and its implications
Ryan K Chung, Angela M Wood, Michael J Sweeting
Journal of the Royal Statistical Society. Series C, Applied Statistics
|
March 19, 2019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Page
of 8
Search research articles
Search
Showing results (1-10 of 73) with videos related to
Sort By:
Page
of 8
Biometrical Journal. Biometrische Zeitschrift
|
April 25, 2017
Using predictions from a joint model for longitudinal and survival data to inform the optimal time of intervention in an abdominal aortic aneurysm screening programme
Michael J Sweeting
Pharmaceutical Statistics
|
March 14, 2012
Escalation strategies for combination therapy Phase I trials
Michael J Sweeting, Adrian P Mander
Statistics in Medicine
|
January 30, 2015
A product of independent beta probabilities dose escalation design for dual-agent phase I trials
Adrian P Mander, Michael J Sweeting
Biometrical Journal. Biometrische Zeitschrift
|
August 12, 2011
Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture
Michael J Sweeting, Simon G Thompson
Plos One
|
July 13, 2016
AplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical Trials
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Statistics in Medicine
|
December 2, 2005
Bayesian back-calculation using a multi-state model with application to HIV
Michael J Sweeting, Daniela De Angelis, Odd O Aalen
Statistics in Medicine
|
April 30, 2004
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data
Michael J Sweeting, Alexander J Sutton, Paul C Lambert
Statistics in Medicine
|
March 16, 2017
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Biometrical Journal. Biometrische Zeitschrift
|
September 4, 2018
Biases incurred from nonrandom repeat testing of haemoglobin levels in blood donors: Selective testing and its implications
Ryan K Chung, Angela M Wood, Michael J Sweeting
Journal of the Royal Statistical Society. Series C, Applied Statistics
|
March 19, 2019
A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data
Graham M Wheeler, Michael J Sweeting, Adrian P Mander
Page
of 8